Compare Enveric Biosciences Inc (ENVB) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs BIO-TECHNE Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 1670.6× Enveric Biosciences Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and BIO-TECHNE Corp for 63 Days on average.
| ENVB | TECH | |
|---|---|---|
Market Cap | $6.80M | $11.36B |
Volume | 64,867 | 5,390,331 |
Sector | Health | Health |
52-Week High | $10.80 | $72.61 |
52-Week Low | $1.27 | $43.31 |
Typical Hold Time | 14 Days | 63 Days |
Enterprise Value | -$1.49M | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
